Filing Details

Accession Number:
0001179110-20-001534
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-02-12 18:00:56
Reporting Period:
2020-02-11
Accepted Time:
2020-02-12 18:00:56
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1235010 Momenta Pharmaceuticals Inc MNTA () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1229450 A Craig Wheeler C/O Momenta Pharmaceuticals, Inc.
301 Binney Street
Cambridge MA 02142
President & Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-02-11 35,302 $13.26 51,159 No 4 M Direct
Common Stock Disposition 2020-02-11 35,302 $32.10 15,857 No 4 S Direct
Common Stock Disposition 2020-02-11 1,773 $31.89 14,084 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2020-02-11 4,124 $0.00 4,124 $13.26
Common Stock Stock Option (Right to Buy) Disposition 2020-02-11 31,178 $0.00 31,178 $13.26
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2015-02-22 2021-02-22 No 4 M Direct
26,475 2013-11-22 2021-02-22 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 36,725 Indirect Craig A Wheeler 2016 Annuity Trust
Common Stock 48,263 Indirect Craig A Wheeler 2018 Annuity Trust
Common Stock 419,934 Indirect Craig Wheeler Revocable Trust
Footnotes
  1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2018.
  2. This transaction was executed in multiple trades at prices ranging from $32.00 to $32.31. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  3. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2016.
  4. This transaction was executed in multiple trades at prices ranging from $31.21 to $32.23. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.